Grifols is experiencing the biggest bearish position in the history of its stock market

Shares of the blood product manufacturer were at 10.69 euros, the highest level in February.instigated Citi report confirms target price of €23 per share. Therefore, the value will be pbullish potential exceeds 100%.

Citi analysts are positive removal of Grifols family members from the gen. organs

Shares of the blood product manufacturer were at 10.69 euros, the highest level in February.instigated Citi report confirms target price of €23 per share. Therefore, the value will be pbullish potential exceeds 100%.

Citi analysts are positive resignation of Grifols family members from the company’s management bodies And appointment of a general director. And also the results of the competitor Grifols, Gemonetics Corporationwhich last Friday reported an 8% increase in revenue from its plasma business and raised its fiscal year billings forecast to a range of 10% to 12%.

In this scenario, Grifols shares will continue on the recovery path after a strong blow occurred on January 9. On this day the promotion lost 25.9% up to 10.55 euros after publication of the report Gotham City Exploration which focused attention on alleged irregularities in the Spanish group’s accounts and questioned the quality of the corporate governance structure.

But Grifols’ actions are not will reach the bottom before January 19, when it was 8.36 euros. The stock has risen nearly 28% since then, but bearish investors believe they can still profit from the closely watched stock.

Despite the stock’s strong rebound from its January lows, hedge funds continue to accumulate short positions in Grifols. The greatest bass player Qube Research launches full-fledged attack. He just raised his short position to 1.19% from 0.71% previously.

Never in its long stock market history has Grifols been shorted at such a high rate. The London fund is practically doubled my bet against the price in 10 daysalready on February 2, 0.61% of the shares were at stake.

In addition, the background Mir Quant has a short position of 0.51%, which has remained unchanged since January 30th. The two funds together represent 1.70% of Grifols, with a joint position valued at approximately €77 million at market value.